All rights reserved). “
“The grants awarded by the British Infection Association (BIA) have recently been reviewed, and applications are currently invited. For further information please visit: http://www.britishinfection.org/drupal/content/british-infection-association-grants. 500 and full sponsorship to attend the FIS Conference.
Deadline for applications: 8th Sept 2014 3-year fellowship. The first BIA/MRC Joint Clinical Research Training Fellowship was awarded in 2011 and the next award will be made at the end of 2014. The successful recipient of this fellowship will take up the funds in spring 2015. Deadline Trametinib mouse for applications: 4pm on Sept 16th 2014 One award of up to £70,000 is available which may include up to £55,000 of salary and up to £15,000 of non-salary costs. Deadline for applications: March 31st 2014 Up to three awards will be made of up to £10,000 per annum for up to 2 years to cover non-salary costs of research only. Deadline for applications: March 31st 2014 Travel, removal and insurance costs up to £5000. Deadline for applications: 31st March 2014 Awards of up to £1000 will be available. These are intended to support trainees presenting at major international conferences. Money will be paid in arrears with receipts and must
be claimed within 1 year. Please note there are three deadlines CH5424802 solubility dmso for applications: 31st March, 30th June and 27th October 2014. One award of up to £1000 will be available to support people travelling from overseas to present their work at FIS 2014. Money will be paid in arrears with receipts and must be claimed within 1 year. Deadline for applications: 30th June 2014 “
“Modern combination highly active antiretroviral therapy (ART) has decreased the morbidity and mortality associated with human immunodeficiency virus type 1 (HIV-1) infection. Low adherence to ART is associated with an increasing risk of resistance to HIV-1 reverse transcriptase inhibitors Flavopiridol (Alvocidib) (RTIs). The emergence of drug resistant virus limits antiretroviral choice due to cross-resistance
to other antiretroviral agents1 and is strongly associated with progression of HIV-1 infection and increased mortality.2, 3, 4, 5 and 6 The cytidine analogues (XTC) emtricitabine (FTC) and lamivudine (3TC) are nucleoside RTIs recommended7, 8, 9, 10 and 11 and widely utilised in the treatment of HIV-1. Fixed dose regimens including dual nucleoside combinations such as FTC + tenofovir disoproxil fumarate (TDF) and 3TC + abacavir (ABC) have simplified ART and are recommended for initial therapy.7, 8, 9, 10 and 11 FTC and TDF have also been formulated as a single tablet regimen with the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz (EFV).12 HIV-1 drug resistance to FTC and 3TC in vivo is mediated by the substitution of the wild type amino acid residue methionine with the amino acid valine at codon 184 (M184V) of reverse transcriptase (RT).